{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:09:40Z","timestamp":1761491380684,"version":"build-2065373602"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Mass Spectrom"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two unknown solution degradants were found during the dissolution testing in 0.1\u2010M HCl for olmesartan medoxomil (OLM) tablets. The structure of the degradants was identified and characterized by liquid chromatography\u2013ultraviolet (LC\u2013UV), liquid chromatography with tandem mass spectrometry (LC\u2013MS\/MS), and nuclear magnetic resonance (NMR) and demonstrated to be cyclization of tetrazole and benzene in the olmesartan (OL) and OLM structures. A series of studies including stress studies, simulation studies, and mechanism\u2010based studies were performed to reveal the potential mechanisms that lead to the formation of the unknown degradants. The study results demonstrated that the degradation was catalyzed with radicals that originated from the metal ions leached from the inner surface of high\u2010performance liquid chromatography (HPLC) glass vials with dissolved oxygen under acidic condition. Prerinsing the glass vials with acidic solution dissolved with EDTA can effectively avoid the generation of such oxidative impurities. The present work provides new insights into the understanding of degradation pathways of OLM, which might support the development of OLM tablets.<\/jats:p>","DOI":"10.1002\/jms.4821","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T01:03:23Z","timestamp":1647219803000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u201cGhost peaks\u201d of olmesartan medoxomil: Two solution degradation products of olmesartan medoxomil via oxidation mediated by metal ions"],"prefix":"10.1002","volume":"57","author":[{"given":"Minxia","family":"Huang","sequence":"first","affiliation":[{"name":"Dongguan HEC Generic Drug R&amp;D Co., Ltd.  Dongguan China"},{"name":"State Key Laboratory of Anti\u2010Infective Drug Development, Sunshine Lake Pharma Co., Ltd.  Dongguan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beiyang","family":"Yao","sequence":"additional","affiliation":[{"name":"Dongguan HEC Generic Drug R&amp;D Co., Ltd.  Dongguan China"},{"name":"State Key Laboratory of Anti\u2010Infective Drug Development, Sunshine Lake Pharma Co., Ltd.  Dongguan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manhua","family":"Jiang","sequence":"additional","affiliation":[{"name":"Dongguan HEC Generic Drug R&amp;D Co., Ltd.  Dongguan China"},{"name":"State Key Laboratory of Anti\u2010Infective Drug Development, Sunshine Lake Pharma Co., Ltd.  Dongguan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuzhou","family":"Sun","sequence":"additional","affiliation":[{"name":"Dongguan HEC Generic Drug R&amp;D Co., Ltd.  Dongguan China"},{"name":"State Key Laboratory of Anti\u2010Infective Drug Development, Sunshine Lake Pharma Co., Ltd.  Dongguan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsong","family":"You","sequence":"additional","affiliation":[{"name":"Dongguan HEC Generic Drug R&amp;D Co., Ltd.  Dongguan China"},{"name":"State Key Laboratory of Anti\u2010Infective Drug Development, Sunshine Lake Pharma Co., Ltd.  Dongguan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Huang","sequence":"additional","affiliation":[{"name":"Dongguan HEC Generic Drug R&amp;D Co., Ltd.  Dongguan China"},{"name":"State Key Laboratory of Anti\u2010Infective Drug Development, Sunshine Lake Pharma Co., Ltd.  Dongguan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Zhao","sequence":"additional","affiliation":[{"name":"Dongguan HEC Generic Drug R&amp;D Co., Ltd.  Dongguan China"},{"name":"State Key Laboratory of Anti\u2010Infective Drug Development, Sunshine Lake Pharma Co., Ltd.  Dongguan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuming","family":"Wu","sequence":"additional","affiliation":[{"name":"Dongguan HEC Generic Drug R&amp;D Co., Ltd.  Dongguan China"},{"name":"State Key Laboratory of Anti\u2010Infective Drug Development, Sunshine Lake Pharma Co., Ltd.  Dongguan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinqian","family":"He","sequence":"additional","affiliation":[{"name":"Dongguan HEC Generic Drug R&amp;D Co., Ltd.  Dongguan China"},{"name":"Ruyuan HEC Pharmaceutical Glass Technology Co., Ltd.  Shaoguan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-5019","authenticated-orcid":false,"given":"Xuezhi","family":"Song","sequence":"additional","affiliation":[{"name":"Dongguan HEC Generic Drug R&amp;D Co., Ltd.  Dongguan China"},{"name":"State Key Laboratory of Anti\u2010Infective Drug Development, Sunshine Lake Pharma Co., Ltd.  Dongguan China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149\u20102918(03)80066\u20108"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.02.021"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2298\/CICEQ111204035J"},{"volume-title":"Stability Testing of New Drug Substances and Products","year":"2003","author":"ICH Guideline, Q1A (R2)","key":"e_1_2_7_5_1"},{"volume-title":"Stability Testing: Photostability Testing of New Drug Substances and Products","year":"1996","author":"ICH Guideline, Q1B","key":"e_1_2_7_6_1"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules201219762"},{"issue":"2","key":"e_1_2_7_8_1","first-page":"103","article-title":"Pharmaceutical glass interactions: a review of possibilities","volume":"8","author":"Pillai SA","year":"2016","journal-title":"J Pharm Sci Res"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1039\/CT8946500899"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1098\/rspa.1934.0221"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021\u20109258(18)65598\u2010X"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/es981171v"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/kin.550060406"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.05.040"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.03.004"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1104\/pp.115.2.527"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajme.2017.09.001"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1039\/9781849735360"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.11.008"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022\u20101902(66)80277\u20104"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.10.038"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10847\u2010012\u20100219\u20104"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2006.11.052"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.11.052"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114248"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2010.11.035"}],"container-title":["Journal of Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jms.4821","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jms.4821","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jms.4821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:23:33Z","timestamp":1760639013000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/jms.4821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/jms.4821"],"URL":"https:\/\/doi.org\/10.1002\/jms.4821","archive":["Portico"],"relation":{},"ISSN":["1076-5174","1096-9888"],"issn-type":[{"type":"print","value":"1076-5174"},{"type":"electronic","value":"1096-9888"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"2021-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e4821"}}